BREAKING! Cold Spring Harbor Phase 2 Clinical Trial Shows That Famotidine Is Effective In Treating COVID-19 Especially In Mild To Moderate Cases!

COVID-19 Drugs: The study findings of a phase 2 clinical trial led by Feinstein Institutes for Medical Research-New York and Cold Spring Harbor Laboratory shows that the common heart burn drug Famotidine is effective in treating COVID-19 disease especially for those with in mild to moderate cases.


 
It should be noted that Thailand Medical News first reported on the potential of using famotidine to treat COVID-19 as early as May 2020 based on study findings from a research led by Columbia University. https://www.thailandmedical.news/news/covid-19-drugs-study-shows-common-and-cheap-heartburn-drug-famotidine-improves-outcomes-of-hospitalized-covid-19-patients
 
Later numerous studies were showed the potential of using famotidine to treat SARS-CoV-2 infections covering the whole spectrum from mild, moderate to hospitalized patients with disease severity. https://www.thailandmedical.news/news/breaking-studies-show-famotidine,-a-common-indigestion-drug-could-help-in-mild-to-moderate-cases-of-covid-19
 
https://www.thailandmedical.news/news/breaking-covid-19-treatments-second-observational-study-shows-famotidine-associated-with-better-outcomes-for-hospitalized-covid-19-patients
 
https://www.thailandmedical.news/news/covid-19-treatments-study-shows-using-dual-antihistamines-such-as-cetirizine-and-famotidine-helps-pulmonary-symptoms-in-covid-19-patients
 
https://www.thailandmedical.news/news/breaking-american-and-german-study-shows-that-heartburn-drug-famotidine-with-aspirin-prevents-covid-19-disease-severity-and-mortality
 
It must be noted that numerous existing approved cheap generic drugs when used in conjunction with other adjuvants, have the potential to treat COVID-19, but unfortunately those controlling the COVID-19 narratives which includes among many others…the Italian Jew…Fauci, the eccentric eugenics advocate…Gates, the mad nazi dog…Schwab, the lower life forms…Obama and Tedros and off course the unethical big pharma decided to find ways to discourage or even cause stop the usage of these drugs along with help from the no longer credible US agencies like the CDC and FDA so that overpriced useless toxic drugs like remdesivir, tocilizumab, molnupiravir, paxlovid and the various monoclonal drugs that are driving mutations and off course the various spike jabs would be used instead.
 
Hence, emerged manipulated studies that only involved a small group of participants with deliberately skewed results to show the ineffectiveness of using famotidine. The first study was conducted by most probably paid garbage Chinese and Asian researchers. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7903022/
 
And the second study was by the pharma company itself Johnson and Johnson as it was in their interest to promote their own vaccines first which has to date been a failure! (Check out what happened to the J & J COVID-19 vaccines online!)
https://pubmed.ncbi.nlm.nih.gov/33982938/

Please help support this website by making a generous donation not only for the sustainability of the website but also for all our research and community initiatives. We are not funded by any entities and really need help. Your help not only saves lives directly but also indirectly. 
https://www.thailandmedical.news/p/sponsorship
 
We off course had the garbage American media like CNN also helping to disrupt the usage of any cheap generic repurposed drugs to treat COVId-19 as they are basically servicing their masters from the democrat party and the big pharma. https://edition.cnn.com/2022/02/10/health/covid-famotidine-study-results/index.html
 
However, this did not deter many professional ethical medical researchers from still exploring the usage of Famotidine in treating COVID-19 and many studies continued.
 
The COVID-19 Drugs study team led by Feinstein Institutes for Medical Research-New York and Cold Spring Harbor Laboratory along with medical and pharma experts from New York City Helath + Hospitals Corporation, Stony Brook University-New York, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell-New York in a phase 2 randomized, double-blind, placebo-controlled clinical trial found that famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19. https://clinicaltrials.gov/ct2/show/NCT04724720
 
The clinical trial was conducted in two different centers in the United States involving unvaccinated adult outpatients with confirmed COVID-19 between January 2021 and April 2021.
 
The patients self-administered 80 mg famotidine (n=28) or placebo (n=27) orally three times a day for 14 consecutive days. Endpoints were time to (primary) or rate of (secondary) symptom resolution, and resolution of inflammation (exploratory).
 
Of 55 patients in the intention-to-treat group (median age 35 years (IQR: 20); 35 women (64%); 18 African American (33%); 14 Hispanic (26%)), 52 (95%) completed the trial, submitting 1358 electronic symptom surveys. Time to symptom resolution was not statistically improved (p=0.4). Rate of symptom resolution was improved for patients taking famotidine (p<0.0001).
 
The study findings showed that estimated 50% reduction of overall baseline symptom scores were achieved at 8.2 days (95% CI: 7 to 9.8 days) for famotidine and 11.4 days (95% CI: 10.3 to 12.6 days) for placebo treated patients. Differences were independent of patient sex, race or ethnicity. Five self-limiting adverse events occurred (famotidine, n=2 (40%); placebo, n=3 (60%)). On day 7, fewer patients on famotidine had detectable interferon alpha plasma levels (p=0.04). Plasma immunoglobulin type G levels to SARS-CoV-2 nucleocapsid core protein were similar between both arms.


Intention-to-treat symptom resolution analyses. (A) The cumulative incidence of total symptom resolution for both study arms as defined in the primary trial endpoint is plotted. The famotidine and placebo arms were compared using stratified log-rank test. (B) The logarithmically transformed patient-level total symptom score (thin lines) and their estimated means based on linear mixed effect model are shown for each study arm. The p value for the interaction term of group and day in study is displayed. (C) The estimated cumulative incidence of symptom resolution for each individual symptom at days 7, 14, 21 and 28 is displayed for each study arm. The results for diarrhoea are not included because neither arm had symptomatic patients at the displayed timepoints. All timepoints with no remaining symptomatic patient are displayed as 100% symptom resolution.
 
The clinical trial findings showed that famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity.
 
The study findings were published in the peer reviewed journal: BMJ Gut
 https://gut.bmj.com/content/early/2022/02/09/gutjnl-2022-326952
 
The study findings also showed that using famotidine in the treatment of outpatients with mild-to-moderate COVID-19, resulting in quick remission of symptoms and inflammation does not lower anti-SARS-CoV-2 immunity.
 
In all a total of 55 adult patients (median age 35 years, 64% female, 33% African American) were randomly assigned to receive either 80 mg famotidine (n=28) or placebo (n=27) three times a day for 14 days. Self-administered treatment was used.
 
Initially, there were no significant differences in total symptom scores (median 18 for both) or average symptom durations across groups (median 4 days for both). Most patients' physiological data were within normal limits, including an average oxygen saturation of 99 percent.
 
The key goal was the time to symptom remission; the rate of symptom resolution was secondary, and the resolution of inflammation was exploratory.
 
The clinical trial was completed by 52 participants (95 percent), who contributed 1,358 electronic symptom surveys. There was no significant improvement in time to symptom resolution with either medication group (p=0.4), although patients taking famotidine had a greater rate of symptom resolution (p0.0001).
 
The clinical trial findings showed that famotidine reduced overall baseline symptom scores by 8.2 days (95 percent confidence interval [CI], 7–9.8) compared to 11.4 days (95 percent confidence interval [CI], 10.3–12.6) with placebo. There were no differences based on gender, race, or ethnicity.
 
Only two patients on famotidine and three on placebo experienced self-limiting adverse effects (40 percent and 60 percent, respectively). On day 7, famotidine patients showed lower interferon alpha plasma levels (p=0.04). The two therapy groups had similar levels of plasma immunoglobulin type G to SARS-CoV-2 nucleocapsid core protein.
 
Corresponding author Dr Tobias Janowitz from Cold Spring Harbor Laboratory added, “Our study has additional strengths. Famotidine is a safe, low-cost and widely available medication with excellent tolerability and minimal known drug–drug interactions that has been taken by millions of patients worldwide. These characteristics are relevant because the number-needed-to-treat to prevent one serious event is high in non-hospitalized patients. Therefore, treatments should have minimal risks, side effects and costs. Our findings should generalize well, given the balanced group of patients from diverse backgrounds, including African American and Hispanic patients, who are at higher risk of poor outcome from COVID-19. We also note that patients in the placebo arm were at higher risk of remaining symptomatic, indicating that famotidine should perhaps be investigated for prevention of long COVID-19. In fact, sustained inflammation may be detrimental in viral diseases other than COVID-19, and the biological effect of H2R blockade may well be transferrable.”
 
He further added, “In accordance with mechanistic laboratory studies, the blockade of H2R causes detectable early recovery of elevated interferon alpha levels in the plasma, presumably by modulating inflammation in organ tissues. Interferon alpha has been linked to ferritin upregulation in non-COVID-19-related clinical studies. The larger increase of ferritin on day 7 in the placebo arm of this study can therefore be explained by a mechanistic sequence. Ferritin has been suggested as a biomarker for COVID-19 and could be used in future famotidine trials.”

Please help support this website by making a generous donation not only for the sustainability of the website but also for all our research and community initiatives. We are not funded by any entities and really need help. Your help not only saves lives directly but also indirectly. 
https://www.thailandmedical.news/p/sponsorship

For more on COVID-19 Drugs, keep on logging to Thailand Medical News.